Print and Electronic Media
CFI is continuing the fight against COVID-19. Below is a collection of written articles that showcase CFI's efforts.
So, what’s your titer?
That question, still strange sounding, may soon become important as vaccines bring about the endgame for COVID-19. Dr. Marc Jenkins talks with Joe Carlson from the Star Tribune on December 7, 2020 about a newly developed blood test made by Imanis Life Sciences in Rochester, MN. The test will give consumers a quantitative measurement of their neutralizing antibody titers that will definitively provide the amount of virus-killing antibodies in their systems . to read the full article.
The Minnesota Daily's Madeline Deninger writes about how Dr. Marc Jenkins and other members of CFI have been working to understand how the body develops antibodies once it has been infected with COVID-19.
CFI director Dr. Marc Jenkins explains how the University of Minnesota and Mayo Clinic are close to unveiling antibody tests that can determine if people have already been infected by the coronavirus that causes COVID-19 and are no longer threats to get or spread the infection. To read the entire Star Tribune article from March 30, 2020 click here.
The Star Tribune's Christopher Snowbeck and CFI's Director Marc Jenkins talk about "a whole new approach to vaccines" using viral RNA instead of the way current vaccines are produced using a weakened or killed form of a virus to stimulate an immune system response that produces antibodies. To read the entire Star Tribune article click here.
Radio and TV
Local News and Seminars
With the FDA approving Pfizer and Moderna booster shots for immunocompromised, Dr. Marc Jenkins spoke with Jay Kolls from KSTP news last night about the vaccine booster for those with weakened immune systems.
Dr. Marc Jenkins, sat down on 7/25/2021 for an extended interview with Chris Hrapsky from Kare11 news to talk about all things COVID19.
Four new studies are helping to answer just how protected people are after a coronavirus infection and how potent a vaccine can be after infection. The research shows good evidence that natural immunity lasts at least a year and could last much longer, according to experts, but it’s unclear if the protection is enough to neutralize several variants of the SARS-CoV-2 virus. Dr. Jenkins and Mr. Hrapsky sit down to discuss these findings and more.
On May 29, 2021 Dr. Marc Jenkins was interviewed by the Star Tribune opinion writer Jill Burcum.
The Star Tribune Editorial Pages have launched "Our Best Shot," an occasions series addressing questions and concerns about COVID-19 vaccine. The Star Tribune Editorial Board enlisted Dr. Jenkins to address concerns about Pfizer and Moderna vaccines' important role in ending the pandemic, as part of its ongoing "Our Best Shot" series tackling vaccine hesitancy. To read the newspaper editorial, go to startribune.com/opinion.
On April 6, 2021 Jeff Wagner from WCCO asked:
Why are many vaccines administered as a shot? Dr. Marc Jenkins has the answer:
“A goal of most vaccines is to induce a strong immune response,” said Dr. Marc Jenkins, director of the Center of Immunology at the University of Minnesota. “And the place in the body where you can do that the best are in organs called lymph nodes.”
Chris Hrapsky from Kare11 and Dr. Marc Jenkins give a quick overview of the types of vaccines that are available and how they work to fight viruses. They also explain the new COVID-19 vaccine and how it is different yet more effective than the old vaccines.
Some cities hand out Keys to the City like the practice is going out of style. The City of Richfield on the other hand only awards Keys to the City to individuals who have made a major impact in the community, State of Minnesota, nation, or in the case of His Holiness the Dalai Lama, the world. This past June, the city council awarded Dr. Marc Jenkins with the key to the city to recognize his accomplishments in the field of immunology, recent election to the National Academy of Sciences, and his work to better public education in Richfield.
On August 11, 2020, for the fifty-second episode of the That’s Rich(field) podcast, we sat down with Dr. Jenkins to discuss his career accomplishments, his research team's recent creation of a COVID-19 antibody test, and what it is like being elected to the National Academy of Sciences.
A new study led by Dr. Kathy Pape from the Jenkins lab is revealing that people who received an mRNA vaccination for COVID19 have greater immune responses compared to others. The study shows differences in immune responses among those vaccinated, including the amount of memory B cells and their vaccine binding performance. Cell Reports paper: z.umn.edu/776f
Thanks to the expertise of the Advanced Research and Diagnostics Laboratory, University scientists and physicians were able to quickly led screenings for # among patients and healthcare workers. ow.ly/bnxP50Ewuks
More than 100 vaccine projects in various stages across the globe take subtly different approaches to achieve the same goal: trigger the body’s immune response to COVID-19 before the virus has an opportunity to spread and cause harm. U of M experts explain three ways to create a COVID-19 vaccine and offer optimism about when we might have a viable option
The University of Minnesota has been hard at work trying to end the COVID-19 pandemic and ease the impact on those affected by it. Read about all the ways that donors, researchers, colleges and students have stepped up to support research and innovation.
SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with non-severe disease
Dr. Tyler Bold led the collaboration of several CFI labs to study the neutralization activity of SARS-CoV-2 antibodies from convalescent plasma in donors with a history of non-severe disease.
A new vaccine development approach, now being studied at the University of Minnesota Medical School, hopes to protect against current and future strains of SARS-CoV-2 (COVID-19). Drs. Geoffrey Hart and Marco Pravetoni have partnered together to prove that a universal vaccine or antibodies are possible in the fight against future variants of SARS-CoV.
Dr. Tyler Bold explains how sera from patients who have recovered from SARS-CoV-2 infection (convalescent sera) could be used immediately to provide protective immunity.
Dr. Karger discusses the need to create and validate the UMN laboratory-developed tests for COVID-19. Marc Jenkins, PhD, and Fang Li, PhD, had laid the foundation for a new antibody (or serology) test but needed a leader and a lab to bring it up for clinical use. Dr. Karger stepped in.